
    
      This study aims to explore the efficacy and safety of Anlotinib plus PD-1 antibody in
      Standard Chemotherapy Failure Advanced Non-small Cell Lung Cancer. We aim to enrolled 100
      patients in this study, the primary endpoint was PFS.
    
  